|
sars-cov-2 |
61 |
|
covid-19 |
56 |
|
antiviral |
30 |
|
coronavirus |
28 |
|
lipidomics |
25 |
|
interferon |
22 |
|
influenza a virus |
21 |
|
enterovirus |
20 |
|
flavivirus |
17 |
|
inhibitor |
17 |
|
sars-cov |
17 |
|
fatty acid |
16 |
|
uplc-esi-q-tof-ms |
16 |
|
animal |
14 |
|
immune activation |
14 |
|
intestine |
14 |
|
protease |
14 |
|
replication |
14 |
|
treatment |
14 |
|
bunyavirales |
13 |
|
live attenuated vaccine |
13 |
|
nsp16 |
13 |
|
zika |
13 |
|
sftsv |
12 |
|
transmission |
12 |
|
2′-o-methyltransferase |
11 |
|
anthranilic acid |
11 |
|
ba.5.2 |
11 |
|
broad spectrum |
11 |
|
endoplasmic reticulum |
11 |
|
human immunodeficiency virus |
11 |
|
influenza virus |
11 |
|
mouse |
11 |
|
mucosal immunity |
11 |
|
murine |
11 |
|
n501y |
11 |
|
neutralizing antibodies |
11 |
|
rat |
11 |
|
sars-cov-2 variants |
11 |
|
sterilizing immunity |
11 |
|
susceptibility |
11 |
|
t-cell response |
11 |
|
adult |
10 |
|
age |
10 |
|
child |
10 |
|
china |
10 |
|
damplicon |
10 |
|
human neutralizing antibody |
10 |
|
linker-immunodominant site |
10 |
|
lung injury |
10 |
|
mers-cov |
10 |
|
nasal turbinate |
10 |
|
omicron |
10 |
|
phage display |
10 |
|
receptor binding domain |
10 |
|
spike protein |
10 |
|
upper respiratory tract |
10 |
|
vaccine |
10 |
|
aged mice |
9 |
|
airway organoid |
9 |
|
animal experiment |
9 |
|
animal model |
9 |
|
antibody-dependent cell-mediated cytotoxicity |
9 |
|
bagg albino mouse |
9 |
|
circrna |
9 |
|
clinical outcome |
9 |
|
controlled study |
9 |
|
coronavac |
9 |
|
ex vivo |
9 |
|
fc-rbd |
9 |
|
genome mutation |
9 |
|
h1n1 influenza virus |
9 |
|
hemagglutinin |
9 |
|
human primary nasal epithelial cells |
9 |
|
human respiratory syncytial virus |
9 |
|
immune protection |
9 |
|
inactivated vaccine |
9 |
|
infectivity |
9 |
|
lethal mouse model |
9 |
|
lung damage |
9 |
|
lung pathology |
9 |
|
mice |
9 |
|
mrna |
9 |
|
neutralizing antibody |
9 |
|
omicron variant |
9 |
|
pb2 |
9 |
|
phosphatidic acid phosphatases |
9 |
|
post-ba.2/5 subvariants |
9 |
|
proximal differentiation |
9 |
|
reverse genetics |
9 |
|
sars-cov-2 variants of concern |
9 |
|
temperature |
9 |
|
weanling mice |
9 |
|
xbb.1 |
9 |
|
25-hydroxycholesterol |
8 |
|
3clpro inhibitor |
8 |
|
allosteric-site inhibitor |
8 |
|
am580 |
8 |
|
animal models |
8 |
|
broad-spectrum antiviral treatment |
8 |
|
chemical genetics |
8 |
|
high throughput screening |
8 |
|
mask |
8 |
|
ns5 |
8 |
|
anti-influenza |
7 |
|
antibody |
7 |
|
betacoronavirus |
7 |
|
bioinorganic chemistry |
7 |
|
bismuth |
7 |
|
bromocriptine |
7 |
|
cell line |
7 |
|
coinfection |
7 |
|
combination therapy |
7 |
|
coronavirus infection |
7 |
|
corticosteroid |
7 |
|
cross-protection |
7 |
|
dendritic cells |
7 |
|
endonuclease activity |
7 |
|
enzyme activation |
7 |
|
epsc |
7 |
|
expanded potential stem cell |
7 |
|
h7n7 virus |
7 |
|
hamster |
7 |
|
hcov-229e |
7 |
|
human |
7 |
|
human trophoblast |
7 |
|
hyperglycemia |
7 |
|
immune response |
7 |
|
immunity |
7 |
|
immunology |
7 |
|
ire1 |
7 |
|
lipid peroxidation |
7 |
|
macrophages |
7 |
|
mdms |
7 |
|
modcs |
7 |
|
monoinfection |
7 |
|
ms |
7 |
|
mutation |
7 |
|
neurogenesis |
7 |
|
nsp14 exon and mtase |
7 |
|
nsp3 |
7 |
|
olfactory neuron |
7 |
|
pa protein |
7 |
|
pan-a37s |
7 |
|
pan-a37s/i61t |
7 |
|
pan-a37s/v63i |
7 |
|
pathogenicity |
7 |
|
polymerase activity |
7 |
|
polymerase assembly |
7 |
|
protein carbonylation |
7 |
|
reinfection |
7 |
|
remdesivir |
7 |
|
spermatogenesis |
7 |
|
t helper 1 responses |
7 |
|
trophoblast organoid |
7 |
|
type 2 diabetes |
7 |
|
uhplc |
7 |
|
upr |
7 |
|
viral replication |
7 |
|
virology |
7 |
|
zika virus |
7 |
|
ar-12 |
6 |
|
artenimol |
6 |
|
broxyquinoline |
6 |
|
eltrombopag |
6 |
|
emerging |
6 |
|
entry |
6 |
|
genome |
6 |
|
hexachlorophene |
6 |
|
huaiyangshan banyangvirus |
6 |
|
influenza |
6 |
|
interactome |
6 |
|
intestinal |
6 |
|
kinase |
6 |
|
molecular modelling |
6 |
|
novobiocin |
6 |
|
omacetaxine mepesuccinate |
6 |
|
orf3a |
6 |
|
organoids |
6 |
|
pathogenesis |
6 |
|
peptide |
6 |
|
platform |
6 |
|
regorafenib |
6 |
|
sars |
6 |
|
sfstv |
6 |
|
sterilising immunity |
6 |
|
tick |
6 |
|
triclosan |
6 |
|
wuhan |
6 |
|
acly |
5 |
|
antiviral peptide |
5 |
|
ba.2.12.1 |
5 |
|
competing endogenous rna |
5 |
|
construction strategies |
5 |
|
delta |
5 |
|
eif4g1 |
5 |
|
ex vivo human lung tissues |
5 |
|
f486v |
5 |
|
glucose homeostasis |
5 |
|
hnpcs |
5 |
|
host−virus interaction |
5 |
|
ido1 |
5 |
|
immunological comparison |
5 |
|
indoleamine 2,3-dioxygenase |
5 |
|
library |
5 |
|
live oral vaccine |
5 |
|
metabolic profiling |
5 |
|
metabolomics |
5 |
|
mirna |
5 |
|
salmonella typhimurium |
5 |
|
sars coronavirus |
5 |
|
soluble and insoluble antigens |
5 |
|
tat |
5 |
|
type-ii ifn |
5 |
|
ace2 |
4 |
|
animal reservoir |
4 |
|
bats |
4 |
|
broad-spectrum antiviral drugs |
4 |
|
drug repurposing |
4 |
|
hnrnp c |
4 |
|
pb2-k389r |
4 |
|
pb2-v598t/i |
4 |
|
pulmonary delivery |
4 |
|
rna binding protein |
4 |
|
severe acute respiratory syndrome coronavirus 2 |
4 |
|
virulence |
4 |
|
alisol b 23-acetate |
3 |
|
anti-coronavirus |
3 |
|
anti-immunoinflammatory activity |
3 |
|
antivirals |
3 |
|
broadly neutralizing antibody |
3 |
|
combinational therapy |
3 |
|
dose optimization |
3 |
|
intrinsic apoptosis |
3 |
|
lethal rsv strain |
3 |
|
monte carlo method |
3 |
|
n-terminal domain |
3 |
|
quaternary epitope |
3 |
|
regression modeling |
3 |
|
respiratory syncytial virus |
3 |
|
rotenone |
3 |
|
subdomain 1 |
3 |
|
antibody-dependent cellular cytotoxicity |
2 |
|
antiviral agents |
2 |
|
aromatic trace amines |
2 |
|
blind docking |
2 |
|
chemical similarity |
2 |
|
colonic secretion |
2 |
|
cross-inhibition |
2 |
|
gastrointestinal motility |
2 |
|
gut microbiota |
2 |
|
hbv |
2 |
|
hnrnpa2b1 |
2 |
|
influenza viruses |
2 |
|
innate immune response |
2 |
|
intranasal delivery |
2 |
|
irritable bowel syndrome |
2 |
|
ligand-based virtual screening |
2 |
|
membrane protein |
2 |
|
molecular dynamics simulations |
2 |
|
neutralising antibody, pulmonary delivery |
2 |
|
pac5 |
2 |
|
pattern recognition receptors |
2 |
|
pharmacophore models |
2 |
|
phenethylamine |
2 |
|
respiratory viral infections |
2 |
|
rna polymerases |
2 |
|
sars-cov-2 omicron |
2 |
|
serotonin |
2 |
|
serum neutralizing activity |
2 |
|
spray drying |
2 |
|
tbk1-irf3 pathway |
2 |
|
trace amine-associated receptor 1 |
2 |
|
tryptamine |
2 |
|
type i ifns |
2 |
|
virus polymerase |
2 |
|
ace2 peptide |
1 |
|
asymptomatic infection |
1 |
|
casual genes |
1 |
|
cholesterol modification |
1 |
|
crystal structure |
1 |
|
cullin-2 ring e3 ligase |
1 |
|
drug design |
1 |
|
evolution |
1 |
|
expression quantitative trait loci |
1 |
|
gwas-eqtl |
1 |
|
histone mimicry |
1 |
|
histone modification |
1 |
|
host range |
1 |
|
hr2 peptide |
1 |
|
integrated strategy |
1 |
|
interspecies transmission |
1 |
|
lipopeptide |
1 |
|
metabolism |
1 |
|
orf10 |
1 |
|
pan-coronavirus fusion inhibitor |
1 |
|
sirna transfection |
1 |
|
spike mutation |
1 |
|
summary data-based mendelian randomization |
1 |
|
synergistic effect |
1 |
|
variants of concern |
1 |
|
viral proteins |
1 |
